8 Ways CROs Support Regulatory Compliance

by | May 16, 2023 | Clinical Trials, CROs, Diagnostics | 0 comments

8 Ways CROs Support Regulatory Compliance

Contract Research Organizations (CROs) play a significant role in supporting regulatory compliance in clinical investigations. Here are several ways CROs support regulatory compliance:

1. Expertise in Regulatory Requirements: CROs have in-depth knowledge of regulatory guidelines and requirements issued by regulatory authorities such as the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA) in the European Union. They stay up-to-date with the latest regulations, ensuring that clinical investigations adhere to all applicable guidelines.

2. Protocol Development: CROs assist in the development of study protocols that comply with regulatory requirements. They ensure that the protocols are scientifically sound, ethically conducted, and align with regulatory expectations. CROs also help investigators navigate the complex regulatory landscape, considering factors such as patient safety, data integrity, and ethical considerations.

3. Regulatory Submissions: CROs support investigators in preparing and submitting regulatory documents, such as Investigational New Drug (IND) applications in the U.S. or Clinical Trial Applications (CTAs) in the EU. They ensure that these submissions are complete, accurate, and comply with the regulatory requirements, including the submission of essential study documentation.

4. Ethics Committee and Institutional Review Board (IRB) Coordination: CROs facilitate the ethical review process by working closely with ethics committees or IRBs. They help investigators prepare the necessary documentation, obtain ethics committee approvals, and address any queries or concerns raised during the review process. CROs ensure that the clinical investigation meets the ethical standards set by regulatory authorities.

5. Monitoring and Auditing: CROs conduct monitoring activities to ensure ongoing regulatory compliance during the clinical investigation. They regularly visit clinical sites to verify that the study is being conducted according to the protocol, applicable regulations, and good clinical practice (GCP) guidelines. Additionally, CROs may perform internal and external audits to identify any compliance gaps and recommend corrective actions.

6. Data Management and Quality Assurance: CROs assist in the collection, management, and analysis of clinical data, ensuring compliance with regulatory requirements for data integrity, confidentiality, and accuracy. They implement quality assurance measures, including data validation and source data verification, to maintain the highest standards of regulatory compliance.

7. Safety Reporting: CROs play a critical role in pharmacovigilance, ensuring the timely and accurate reporting of adverse events (AEs) and serious adverse events (SAEs) during the clinical investigation. They adhere to regulatory guidelines on safety reporting, collaborate with investigators to collect and assess safety data, and submit required safety reports to regulatory authorities as per the regulations.

8. Regulatory Inspections and Audits: CROs support investigators during regulatory inspections and audits. They help prepare for these inspections, respond to regulatory queries, and address any findings or observations raised by the regulatory authorities. CROs assist in maintaining audit readiness and ensure compliance with regulatory requirements throughout the investigation.

Overall, CROs act as partners to investigators, providing comprehensive support to ensure regulatory compliance in clinical investigations. They bring expertise, experience, and efficient processes to assist investigators in meeting regulatory requirements at every stage of the study.

Bergein Overholt, M.D.

Dr. Bergein Overholt is widely recognized for his work as the developer of the flexible fiber sigmoidoscope-colonoscope in 1963, which is used in colonoscopy while serving in the Cancer Control Program of the U.S. Public Health Service. For his innovative work, he was...

Herbert A. Fritsche, PhD

Dr. Herbert Fritsche is Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center in Houston, Texas. During his 40+ years at M.D. Anderson Cancer Center, Dr. Herbert Fritsche has focused his...

Eric Allyn

Eric Allyn will be a non-Director Board Observer and is the former Chairman of the Board of Directors of Welch Allyn, Inc, a company owned by the Allyn Family for 100 years. In September of 2015, as a result of tremendous consolidation in health care, Welch Allyn sold...

Tom Boyd

Tom Boyd will be a non-Director Board Observer and is the former Chairman of the Company. Tom Boyd was a member of the Company’s Board of Directors since it was incorporated in April 2005, and was the Company’s Chief Executive Officer from April 2005 to April 2014. He...

Paolo Rubatto

Paolo Rubatto is the founder of Start Capital, a London-based early-stage investment firm that invests globally. In addition, he is a co-founder and general partner at Beyond Ventures and an advisor at ScalingLab. Paolo has invested in and advised numerous technology...

Scott Gucciardi

Scott Gucciardi is a Senior Vice President of Solutions at Nextgen Healthcare (NASDAQ: NXGN). Scott Gucciardi is an executive and entrepreneur with over 25 years of experience in the global medical device and health information technology solutions markets. Scott...

Autumn R. Anfang

Autumn Anfang is a highly experienced financial executive with over 25 years of leadership experience in various sectors including for-profit, non-profit, and higher education institutions. She currently serves as the Vice President of Business and Finance and Chief...

Contact us

Call Us

(255) 352-6258

Email Us


Our Location

5678 Extra Rd. #123
San Francisco, CA 96120

Get in touch